Logo

Novacyt: James McCarthy, Anthony Dyer

Jan 05, 2021

Clinical diagnostics firm Novacyt has appointed James McCarthy as its CFO and Anthony Dyer to a new role as its chief corporate development officer. McCarthy will become a board director, subject to shareholder approval at the company's annual general meeting. Dyer will remain a board director until then.

McCarthy has held senior positions in listed and private equity-backed businesses. He was CFO of Flint Group, and of Brambles' Europe, Middle East, and Africa-based Commonwealth Handling Equipment Pool (CHEP) business before being promoted to president of CHEP’s European team.

McCarthy trained as an accountant with Dairygold and has worked for Unilever and ICI, among other companies.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.